-
Ligand, Spectrum Pharmaceuticals in Global License Agreement
Thursday, March 14, 2013 - 7:02am | 140Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of global license and supply agreements with Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) for the development and commercialization of Ligand's Captisol-enabled®, propylene glycol-free (PG-free...
-
Stocks Hitting 52-Week Highs
Monday, February 11, 2013 - 11:30am | 107Nasdaq OMX Group (NASDAQ: NDAQ) shares gained 0.68% to create a new 52-week high of $29.67. Nasdaq OMX's PEG ratio is 1.02. PCM (NASDAQ: PCMI) shares created a new 52-week high of $7.123. PCM's trailing-twelve-month revenue is $1.46 billion. Neurocrine Biosciences (NASDAQ: NBIX) shares touched a...
-
Earnings Scheduled For February 8, 2013
Friday, February 8, 2013 - 3:31am | 500American Axle & Manufacturing Holdings (NYSE: AXL) is expected to report its Q4 earnings at $0.10 per share on revenue of $729.35 million. Beacon Roofing Supply (NASDAQ: BECN) is projected to report its Q1 earnings at $0.41 per share on revenue of $525.50 million. AOL (NYSE: AOL) is estimated...
-
Ligand Pharma Wins Equity Milestone Payment from Retrophin
Wednesday, January 9, 2013 - 10:01am | 219Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has received a milestone payment of 620,000 shares of common stock in newly public partner Retrophin, Inc.The milestone arose under the previously executed license agreement for the development and commercialization of...
-
Benzinga's Top Pre-Market Gainers
Monday, December 17, 2012 - 9:21am | 143Lexicon Pharmaceuticals (NASDAQ: LXRX) surged 10.70% to $2.07 in the pre-market session. Lexicon Pharmaceuticals reported that it has received "Fast Track" status from the FDA for the development of LX1033. Ariad Pharmaceuticals (NASDAQ: ARIA) added 3.48% to $19.59 in the pre-market session. ARIAD...
-
Lexicon Pharma Shares Rise Following FDA Fast Track Designation for LX1033 for IBS
Monday, December 17, 2012 - 8:50am | 210Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has received "Fast Track" status from the U.S. Food and Drug Administration (FDA) for the development of LX1033, an...
-
FDA Accepts NDA for Pfizer, Ligand's Bazedoxifene/Conjugated Estrogens
Thursday, December 13, 2012 - 6:05pm | 181Pfizer Inc. (NYSE: PFE) and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the United States Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for non-hysterectomized...
-
Ligand Pharma Begins Pivotal Trial of Captisol-Enabled Propylene Glycol-Free Melphalan for Multiple Myeloma Patients
Monday, December 10, 2012 - 5:09pm | 142Ligand Pharma (NASDAQ: LGND) announced today that it has initiated a pivotal trial of Captisol-enabled^®, propylene glycol-free (PG-free) high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma. This multi-center trial will evaluate safety...
-
Benzinga's Small Cap Movers for Thursday December 6, 2012
Thursday, December 6, 2012 - 9:53pm | 451Below are highlights from Benzinga's daily coverage of small cap securities making big moves: Metabolix Shares of Metabolix (NASDAQ: MBLX), the Cambridge, MA bioscience company delivering sustainable solutions to the plastics, chemicals and energy industries, rose 45% Thursday on 10 times average...
-
Morning Market Movers
Wednesday, December 5, 2012 - 10:50am | 138McMoRan Exploration Co (NYSE: MMR) climbed 74.49% to $14.76 at 9:45 am. Freeport-McMoRan Copper & Gold (NYSE: FCX) is considering to buy McMoRan Exploration and a large oil and gas company, according to The Financial Times. Mitek Systems (NASDAQ: MITK) surged 34.17% to $3.22. US Bank and Mitek...
-
Benzinga's Volume Movers
Monday, November 19, 2012 - 11:46am | 184Ligand Pharmaceuticals (NASDAQ: LGND) shares moved up 13.98% to $19.00 at 10:40 am. The volume of Ligand Pharmaceuticals shares traded was 1663% higher than normal. Ligand Pharmaceuticals partner GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has...
-
Ligand Pharma, Glaxo Confirm PROMACTA Receives FDA Ok for New Indication
Monday, November 19, 2012 - 10:11am | 113Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to...
-
Ligand Pharma Announces Preclinical Data for LG-7501
Tuesday, November 13, 2012 - 10:08am | 204Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that data from preclinical studies evaluating LG-7501 were featured in a poster presentation today at the 63^rd Annual Meeting of the American Association for the Study of Liver Diseases in Boston. Ligand is developing novel small...
-
Lexicon Pharma Says Primary Efficacy Endpoint Was Achieved
Tuesday, November 6, 2012 - 11:34am | 85Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions...
-
Ligand to Receive $2 Million Milestone Payment from Merck; Re-Affirms FY Forecast
Monday, October 22, 2012 - 8:31am | 200Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it will receive a $2 million milestone payment from Merck, known as MSD outside the United States and Canada, under the terms of a development and license collaboration for the development of dinaciclib. This milestone payment...